CLICK HERE FOR MPS MEMBER TICKETS (FREE!)
CLICK HERE FOR NON-MEMBER TICKETS ($25)
7:00-7:45 Frederick Nucifora, M.D.
7:45-8:15 Paul Kim, Ph.D., M.D.
8:15-8:45 Robert Buchanan, MD
8:45-9:00 Question and Answer Session
Objectives: A the conclusion of the activity participants will be able to:
- Highlight advances from pharmacogenetic studies on clozapine and then focus on studies of clozapine using unbiased approaches such as pharmacogenomics and gene expression profiling.
- Describe recent advances in the use of Long-Acting Injectable Antipsychotics.
- Recognize Ketamine’s antidepressant mechanism of action
In support of improving patient care, this activity has been planned and implemented by American
Psychiatric Association (APA) and The Maryland Psychiatric Society. The
American Psychiatric Association (APA) is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing education for the
The American Psychiatric Association (APA) designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Thank you to our supporters: